These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 7051805)

  • 21. Multiple trials of adjuvant chemohormonal therapy in the treatment of breast cancer: preliminary results--the ECOG experience.
    Carbone PP
    Breast Cancer Res Treat; 1983; 3 Suppl():S35-8. PubMed ID: 6367858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
    Chang YC; Falkson G; Tormey DC; Crowley J
    Cancer Clin Trials; 1981; 4(4):377-80. PubMed ID: 6797746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU).
    Fisher B; Glass A; Redmond C; Fisher ER; Barton B; Such E; Carbone P; Economou S; Foster R; Frelick R; Lerner H; Levitt M; Margolese R; MacFarlane J; Plotkin D; Shibata H; Volk H
    Cancer; 1977 Jun; 39(6 Suppl):2883-903. PubMed ID: 194679
    [No Abstract]   [Full Text] [Related]  

  • 24. The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy.
    Griem KL; Henderson IC; Gelman R; Ascoli D; Silver B; Recht A; Goodman RL; Hellman S; Harris JR
    J Clin Oncol; 1987 Oct; 5(10):1546-55. PubMed ID: 3309196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
    Camoriano JK; Loprinzi CL; Ingle JN; Therneau TM; Krook JE; Veeder MH
    J Clin Oncol; 1990 Aug; 8(8):1327-34. PubMed ID: 2199619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.
    Weiss RB; Woolf SH; Demakos E; Holland JF; Berry DA; Falkson G; Cirrincione CT; Robbins A; Bothun S; Henderson IC; Norton L;
    J Clin Oncol; 2003 May; 21(9):1825-35. PubMed ID: 12721260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
    Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
    Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.
    Ingle JN; Everson LK; Wieand HS; Martin JK; Votava HJ; Wold LE; Krook JE; Cullinan SA; Paulsen JK; Twito DI
    J Clin Oncol; 1988 Sep; 6(9):1388-96. PubMed ID: 3047333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.
    Gianni AM; Siena S; Bregni M; Di Nicola M; Orefice S; Cusumano F; Salvadori B; Luini A; Greco M; Zucali R; Rilke F; Zambetti M; Valagussa P; Bonadonna G
    J Clin Oncol; 1997 Jun; 15(6):2312-21. PubMed ID: 9196145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3 cm.
    Calais G; Berger C; Descamps P; Chapet S; Reynaud-Bougnoux A; Body G; Bougnoux P; Lansac J; Le Floch O
    Cancer; 1994 Aug; 74(4):1283-8. PubMed ID: 8055449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study.
    Glucksberg H; Rivkin SE; Rasmussen S; Tranum B; Gad-el-Mawla N; Costanzi J; Hoogstraten B; Athens J; Maloney T; McCracken J; Vaughn C
    Cancer; 1982 Aug; 50(3):423-34. PubMed ID: 7046900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant systemic therapy for resectable breast cancer.
    Bonadonna G; Valagussa P
    J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562
    [No Abstract]   [Full Text] [Related]  

  • 33. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer.
    Fisher B; Fisher ER; Redmond C
    J Clin Oncol; 1986 Jun; 4(6):929-41. PubMed ID: 3519883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemotherapy with or without oophorectomy in high-risk premenopausal patients with operable breast cancer.
    Ludwig Breast Cancer Study Group
    J Clin Oncol; 1985 Aug; 3(8):1059-67. PubMed ID: 2862223
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ten-year experience with CMF-based adjuvant chemotherapy in resectable breast cancer.
    Bonadonna G; Valagussa P; Rossi A; Tancini G; Brambilla C; Zambetti M; Veronesi U
    Breast Cancer Res Treat; 1985; 5(2):95-115. PubMed ID: 3839424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A; Gelber R
    NCI Monogr; 1986; (1):55-70. PubMed ID: 3774016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
    Mansour EG; Eudey L; Tormey DC; Shatila AH; Osborne CK; Gilchrist KW; Cooper MR; Falkson G
    J Natl Cancer Inst Monogr; 1992; (11):97-104. PubMed ID: 1627437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer.
    Buckner JC; Ingle JN; Everson LK; O'Fallon JR; Cullinan SA; Ahmann DL; Krook JE; Pfeifle DM
    Breast Cancer Res Treat; 1989 Mar; 13(2):135-42. PubMed ID: 2659104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis.
    Ahmann DL; Green SJ; Bisel HF; Ingle JN; Hahn RG; Lee RA; Edmonson JH
    Am J Clin Oncol; 1982 Aug; 5(4):355-8. PubMed ID: 7051804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.